Precision BioSciences, Inc. (NASDAQ:DTIL) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have been given a consensus rating of “Moderate Buy” by the five research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $32.25.

A number of equities analysts have recently weighed in on DTIL shares. Wall Street Zen lowered Precision BioSciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Finally, Oppenheimer started coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price objective on the stock.

Precision BioSciences Stock Performance

NASDAQ DTIL opened at $8.85 on Friday. The stock has a market cap of $244.26 million, a PE ratio of -3.16 and a beta of 1.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 12.82 and a current ratio of 12.82. The firm has a 50-day moving average of $7.64 and a 200-day moving average of $6.60. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. On average, sell-side analysts anticipate that Precision BioSciences will post -3.33 EPS for the current year.

Hedge Funds Weigh In On Precision BioSciences

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new stake in Precision BioSciences in the 2nd quarter worth about $467,000. Bank of America Corp DE grew its position in shares of Precision BioSciences by 167.6% during the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after purchasing an additional 17,172 shares in the last quarter. Quantinno Capital Management LP acquired a new position in shares of Precision BioSciences during the 1st quarter worth approximately $104,000. Octagon Capital Advisors LP increased its holdings in shares of Precision BioSciences by 16.6% during the first quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after purchasing an additional 318,737 shares during the period. Finally, Affinity Asset Advisors LLC bought a new position in shares of Precision BioSciences during the first quarter worth approximately $3,289,000. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.